These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34023215)

  • 21. Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation.
    Scott AA; Yarney J; Vanderpuye V; Akoto Aidoo C; Agyeman M; Boateng SN; Sasu E; Anarfi K; Obeng-Mensah T
    Int J Gynecol Cancer; 2021 May; 31(5):670-678. PubMed ID: 33558421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002).
    Gultekin M; Beduk Esen CS; Balci B; Alanyali S; Akkus Yildirim B; Guler OC; Yuce Sari S; Ergen SA; Sahinler I; Alsan Cetin I; Onal C; Yildiz F; Ozsaran Z
    Int J Gynecol Cancer; 2021 Feb; 31(2):185-193. PubMed ID: 32998860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.
    Chen SW; Liang JA; Yang SN; Ko HL; Lin FJ
    Radiother Oncol; 2003 Apr; 67(1):69-76. PubMed ID: 12758242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
    Ka K; Laville A; Rassy E; Ayachi RE; Pautier P; Ba MB; Bockel S; Achkar S; Espenel S; Maulard A; Morice P; Gouy S; Haie-Meder C; Sun R; Chargari C
    Gynecol Oncol; 2023 Jan; 168():32-38. PubMed ID: 36370612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
    Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
    Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
    Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of single insertion accelerated MR-image guided brachytherapy following chemo-radiation in locally advanced cervix cancer: modifying our EMBRACE during the COVID pandemic.
    Stevens MJ; Ko F; Martland J; Brown R; Bell L; Atyeo J; Yim J
    Radiat Oncol; 2023 Mar; 18(1):54. PubMed ID: 36941643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.
    Lee HJ; Kim YS; Shin SS; Nam JH; Kim YT; Han S; Choi EK
    Tumori; 2012; 98(5):615-21. PubMed ID: 23235757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes.
    Tinkle CL; Weinberg V; Chen LM; Littell R; Cunha JAM; Sethi RA; Chan JK; Hsu IC
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1093-1100. PubMed ID: 26194683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of different treatment plans on EQD
    Gul OV; Inan G; Basaran H
    J Egypt Natl Canc Inst; 2021 Oct; 33(1):28. PubMed ID: 34604928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
    Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
    Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
    Sood BM; Gorla G; Gupta S; Garg M; Deore S; Runowicz CD; Fields AL; Goldberg GL; Anderson PS; Vikram B
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):702-6. PubMed ID: 12062615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial.
    Murakami N; Watanabe M; Uno T; Sekii S; Tsujino K; Kasamatsu T; Machitori Y; Aoshika T; Kato S; Hirowatari H; Kaneyasu Y; Nakagawa T; Ikushima H; Ando K; Murata M; Yoshida K; Yoshioka H; Murata K; Ohno T; Okonogi N; Saito A; Ichikawa M; Okuda T; Tsuchida K; Sakurai H; Yoshimura R; Yoshioka Y; Yorozu A; Okamoto H; Inaba K; Kato T; Igaki H; Itami J
    Jpn J Clin Oncol; 2022 Aug; 52(8):859-868. PubMed ID: 35470390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients.
    Bronsart E; Petit C; Gouy S; Bockel S; Espenel S; Kumar T; Fumagalli I; Maulard A; Ayachy RE; Genestie C; Leary A; Pautier P; Morice P; Haie-Meder C; Chargari C
    Cancer Radiother; 2020 Dec; 24(8):860-865. PubMed ID: 33129715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution in the management of locally advanced cervical cancer: the experience of Cancer Institute (WIA), Chennai, India.
    Shanta V; Selvaluxmy G; Swaminathan R; Shanthi P
    Asian Pac J Cancer Prev; 2010; 11(4):1091-8. PubMed ID: 21133630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
    Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.